title: Cotransfection of survivin and CD44v3 short hairpin RNAs affects proliferation, apoptosis, and invasiveness of colorectal cancer.
abstract: BACKGROUND
  Colorectal cancer is one of the common malignant tumors in humans, and the incidence rate is gradually increasing year by year. Survivin and CD44v3 are ideal targets for gene therapy due to their overexpression in colorectal cells. Studies show that downregulation of survivin could promote apoptosis and depress proliferation, and reduction of CD44v3 expression could inhibit tumor invasive capacity. It is difficult to achieve satisfactory curative effect.
  
  
  OBJECTIVE
  In this study, we use survivin and CD44v3 short hairpin RNAs (shRNA) combined transfection into colorectal cancer cell line SW480 to investigate its effects on the cell apoptosis, proliferation and invasiveness.
  
  
  METHODS
  ShRNA plasmids targeting survivin and CD44v3 were singly or co-transfected into SW480 cells.
  
  
  RESULTS
  The co-transfection group exhibited the most significant inhibitory effect on cell growth (P < 0.05) and the highest apoptosis rate (P < 0.05). In addition, the invasive capacity in the co-transfected group was the least. The tumor inhibition rate of the cotransfected group in xenograft tumor mice was significantly higher than other groups (P < 0.05). Moreover, the microvessel density of the co-transfected group was significantly decreased compared with other groups (P < 0.05).
  
  
  CONCLUSIONS
  These results suggest combined transfection of survivin shRNA and CD44v3 shRNA may produce a synergistic effect on gene therapy in colorectal cancer.
authors: The Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Nangang District, Harbin, 150086, China. zhaoyy@sj-hospital.org
authors: Zhonghong
authors: Z
authors: Liu
authors: Yonghang
authors: Y
authors: Guo
authors: Juan
authors: J
authors: Li
authors: Jun
authors: J
authors: Xu
authors: Bingrong
authors: B
authors: Liu
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics*; D020287:In Situ Nick-End Labeling; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D051379:Mice; D008819:Mice, Nude; D009361:Neoplasm Invasiveness / Q000235:genetics; D034741:RNA, Small Interfering; D011897:Random Allocation; D000077022:Survivin; D014162:Transfection / Q000379:methods*; D016896:Treatment Outcome
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; C121450:CD44V3,8-10; D018960:Hyaluronan Receptors; D051034:Inhibitor of Apoptosis Proteins; D034741:RNA, Small Interfering; D000077022:Survivin
references: Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jul;40(4):569-74
references: 19764546
references: Cancer Gene Ther. 2006 Jun;13(6):563-71
references: 16410825
references: Clin Cancer Res. 2000 Jan;6(1):127-34
references: 10656440
references: Int J Mol Med. 2002 Sep;10(3):333-7
references: 12165810
references: Oncogene. 2004 Apr 12;23(16):2825-37
references: 15077146
references: J Cell Mol Med. 2005 Apr-Jun;9(2):360-72
references: 15963255
references: Lancet. 2003 Jul 19;362(9379):205-9
references: 12885482
references: Adv Cancer Res. 2003;88:31-52
references: 12665052
references: Int J Mol Med. 2009 May;23(5):639-49
references: 19360323
references: Cancer Lett. 2006 Jun 8;237(1):10-21
references: 16002209
references: Cell. 1998 Nov 13;95(4):461-70
references: 9827799
references: Crit Rev Oncol Hematol. 2006 Feb;57(2):107-21
references: 16326109
references: Strahlenther Onkol. 2002 Aug;178(8):426-35
references: 12240548
references: Int J Mol Med. 2009 Nov;24(5):677-83
references: 19787202
references: J Biol Chem. 2004 Feb 13;279(7):5655-60
references: 14610074
references: Cancer Lett. 2001 Feb 10;163(1):95-101
references: 11163112
references: Lancet. 1993 Oct 23;342(8878):1019-22
references: 7692200
references: J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):84-91
references: 16706817
references: World J Gastroenterol. 2003 May;9(5):974-7
references: 12717841
references: Head Neck. 2007 Jun;29(6):550-8
references: 17252589
references: J Biol Chem. 2002 Feb 15;277(7):4589-92
references: 11717317
references: Exp Cell Res. 2001 May 15;266(1):167-76
references: 11339835
references: Gut. 2000 May;46(5):645-50
references: 10764707
references: Oligonucleotides. 2004;14(2):100-13
references: 15294074
references: Matrix Biol. 2002 Jan;21(1):15-23
references: 11827788
references: Toxicol Sci. 2002 Apr;66(2):233-43
references: 11896290
references: Biochem Biophys Res Commun. 2005 Jun 10;331(3):718-25
references: 15865928
references: Clin Cancer Res. 2001 Dec;7(12):4067-72
references: 11751503